Min Li

SciNeuro Pharmaceuticals is a Chinese clinical-stage biotechnology company that focuses on developing therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's disease. SciNeuro Pharmaceuticals is based in Shanghai, China, and has corporate and R&D facilities located in both Shanghai and Beijing. SciNeuro has built a portfolio of pipeline programs that address three key disease-driving mechanisms of neurodegeneration. The company is committed to delivering medicines that can make a difference in the lives of patients around the world. The company is an innovation-driven, neuroscience-focused biopharmaceutical company that uses in-house discovery and development to create innovative therapeutics for neurodegenerative and other CNS diseases. The company was founded in 2020 by Min Li, who has been the CEO since then.

Novotech Health Holdings Ltd. operates as a biotech-focused full-service contract research organization. Its integrated CRO platform provides clinical trial services ranging from consulting services prior to the commencement of the clinical phase to late-phase clinical trials. The firm’s services include: clinical trial services which include clinical research, bioequivalence and pharmacodynamics research, and drug development consulting services; and its related clinical trial services which include laboratory, site management organization, flexible insourcing and Phase I clinical trial unit services. The company was founded on February 25, 2020 and is headquartered in Singapore.